CDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing authorization from Lithuania’s State Medicines Control Agency within six months.
The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027.
Danish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the peptide into phase 2 testing in 2027.
Dutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year.
Next-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding immune reactions (seen with many viral vectors) or undesired organ accumulation (evidenced with LNPs in the liver). Scientists are now harnessing a technology that could overcome these hurdles by using vesicles that cells naturally produce: exosomes.
Switzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into roughly the same efficacy range as several leading injected treatments.
Novartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in the Phase 3 HARBOR study in myotonic dystrophy type 1.
North Rhine-Westphalia (NRW), a state located in the North-West of Germany, is investing €200 million to connect university hospitals in Aachen, Bochum, Bonn, Düsseldorf, Essen, Cologne and Münster, as well as the Technical University Dortmund in an AI network for cancer medicine.
Spanish biotech Vaxdyn has raised an €11 million Series A to take K-VAX, its vaccine against Klebsiella pneumoniae and Acinetobacter baumannii, into a first-in-human Phase 1 trial. Portuguese investor Biovance Capital led the round with a €4 million investment, joined by the European Innovation Council (EIC) Fund and the Impacto Andalusia fund managed by Arcano Partners.
Copenhagen’s BioInnovation Institute (BII) is providing six early-stage companies with €1.3 million each in convertible loans, taking its total financing of each startup to €1.8 million.